Avidity Biosciences CMO Hughes Buys, Sells Shares at $10.16 and $46.4

Avidity Biosciences, Inc., a biotechnology company focused on RNA therapeutics, has announced that Chief Medical Officer Hughes Steven George has made a significant transaction involving the company's shares. Specifically, on August 22, 2025, Hughes Steven George purchased 2208 shares of Avidity Biosciences at a price of $10.16 per share. Conversely, on the same day, he also sold 2208 shares of the company at a price of $46.4 per share. This transaction is noteworthy, as it highlights Hughes Steven George's confidence in the company's future prospects and potential for growth.

Title: Avidity Biosciences' Chief Medical Officer Makes Significant Share Transactions

Avidity Biosciences, Inc., a biotechnology company focused on RNA therapeutics, has seen notable activity in its share transactions. On August 22, 2025, Chief Medical Officer Hughes Steven George executed a significant transaction involving the company's shares. Specifically, he purchased 2208 shares at a price of $10.16 per share and simultaneously sold 2208 shares at a price of $46.4 per share on the same day.

This transaction underscores Hughes Steven George's confidence in Avidity Biosciences' future prospects and potential for growth. The purchase of shares at a lower price suggests a belief in the company's long-term value, while the sale at a higher price indicates a strategic move to capitalize on recent market appreciation.

Market Trends and Insider Activity

Avidity Biosciences has been attracting attention from both institutional investors and analysts. Over the last 90 days, insiders have sold a significant number of shares, totaling 453,826 shares valued at $20,063,286. This increased selling activity among insiders may indicate a cautious outlook or strategic repositioning within the company [2].

Meanwhile, institutional investors have shown interest in Avidity Biosciences. TD Waterhouse Canada Inc. grew its stake by 646.3% during the 4th quarter, while Parallel Advisors LLC and GF Fund Management CO. LTD. also increased their holdings. This increased institutional interest could be a signal of confidence in the company's prospects [2].

Analyst Ratings and Market Sentiment

Several analysts have recently commented on Avidity Biosciences' stock. Wolfe Research, Evercore ISI, Chardan Capital, Cantor Fitzgerald, and JPMorgan Chase & Co. have all issued positive ratings and price targets for the stock. The consensus rating among analysts is "Buy," with an average target price of $67.00 [2].

Breakthrough Therapy Designation

Avidity Biosciences has made significant strides in the development of RNA therapeutics. The company's lead product candidate, AOC 1001, is in phase 1/2 clinical trials for the treatment of myotonic dystrophy type 1. Additionally, Avidity Biosciences' investigational treatment delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy has been granted Breakthrough Therapy designation by the FDA. This recognition signals momentum for next-gen RNA therapeutics designed to enhance delivery and efficacy in treating rare genetic diseases [3].

Conclusion

Hughes Steven George's share transactions highlight the potential for growth and confidence in Avidity Biosciences' future prospects. The company's strategic positioning and strong market interest from both institutional investors and analysts underscore its promising outlook. With ongoing clinical trials and breakthrough therapy designations, Avidity Biosciences is poised to make significant strides in the RNA therapeutics market.

References
[1] https://www.smartkarma.com/insights/china-healthcare-weekly-aug-17-glp-1s-inflection-point-novartis-to-acquire-avidity-biosciences?utm_medium=feed&utm_source=RSS
[2] https://www.marketbeat.com/instant-alerts/filing-avidity-biosciences-inc-rna-shares-sold-by-swiss-national-bank-2025-08-20/
[3] https://www.drugdiscoverynews.com/fda-grants-breakthrough-therapy-designation-to-first-in-class-aoc-therapeutic-for-duchenne-muscular-dystrophy-16530